PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26370958-8	2015	SVR can be predicted through core and NS5A region mutations and host factors like hemoglobin, platelet count, and AST/ALT ratio in HCV genotype 1b-infected patients treated with peginterferon and ribavirin combination therapy.	peginterferon	178-191	solute carrier family 17 member 5	Homo sapiens	114-117
25798824-1	2015	It was reported that dual specificity phosphatase 1 (DUSP1) is specifically upregulated in the liver of patients with chronic hetpatitis C virus (HCV) infection who do not respond to peginterferon (PegIFN) treatment.	peginterferon	183-196	dual specificity phosphatase 1	Homo sapiens	21-51
25798824-1	2015	It was reported that dual specificity phosphatase 1 (DUSP1) is specifically upregulated in the liver of patients with chronic hetpatitis C virus (HCV) infection who do not respond to peginterferon (PegIFN) treatment.	peginterferon	183-196	dual specificity phosphatase 1	Homo sapiens	53-58
31685739-3	2019	In this study, we compared the QOL between patients treated with LDV/SOF and those treated with simeprevir (SMV)/peginterferon (Peg-IFN)/RBV to provide QOL information in clinical practice.	peginterferon	113-126	interferon alpha 1	Homo sapiens	132-135
32744512-2	2020	We aimed to study whether HBcrAg levels predict response to peginterferon (PEG-IFN) treatment in HBeAg positive chronic hepatitis B (CHB) patients.	peginterferon	60-73	capsid protein;pre-capsid protein	Hepatitis B virus	97-102
30043870-4	2018	OBJECTIVE: To evaluate the impact of insulin resistance on sustained virological response in HCV genotype 3 patients treated with peginterferon/ribavirin.	peginterferon	130-143	insulin	Homo sapiens	37-44
25586058-2	2016	The aim of this study was to determine the performance of anti-HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with peginterferon (Peg-IFN) or nucleos(t)ide analogues (NUCs), respectively.	peginterferon	175-188	keratin 88, pseudogene	Homo sapiens	63-66
23874902-1	2013	BACKGROUND/AIMS: Single-nucleotide polymorphisms (SNPs) near the interleukin 28B gene (IL28B; interferon [IFN]-lambda-3) are associated with outcomes of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection treated with peginterferon (PEG-IFN) alpha-based antiviral therapy.	peginterferon	236-249	interferon lambda 3	Homo sapiens	87-92
23735127-1	2013	In 2011, the protease inhibitors (PIs) boceprevir and telaprevir in combination with peginterferon (peg-IFN) and ribavirin (RBV) were the first direct-acting antivirals (DAAs) approved in the United States for treatment of genotype (GT) 1 HCV.	peginterferon	85-98	interferon alpha 1	Homo sapiens	104-107
23386076-8	2013	The use of erythropoietin-stimulating agents has been shown to be effective for anemia caused by peginterferon and ribavirin without compromising SVR rates.	peginterferon	97-110	erythropoietin	Homo sapiens	11-25
23321318-1	2013	BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naive patients treated with peginterferon/ribavirin (PegIFN/RBV).	peginterferon	197-210	interferon lambda 3	Homo sapiens	81-86
23918539-1	2013	This study aimed to evaluate whether genetic polymorphisms of the inducible nitric oxide synthase (iNOS) gene NOS2A could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV).	peginterferon	285-298	nitric oxide synthase 2	Homo sapiens	66-97
23918539-1	2013	This study aimed to evaluate whether genetic polymorphisms of the inducible nitric oxide synthase (iNOS) gene NOS2A could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV).	peginterferon	285-298	nitric oxide synthase 2	Homo sapiens	99-103
23918539-1	2013	This study aimed to evaluate whether genetic polymorphisms of the inducible nitric oxide synthase (iNOS) gene NOS2A could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV).	peginterferon	285-298	nitric oxide synthase 2	Homo sapiens	110-115
23651608-2	2013	This study aimed to evaluate whether genetic polymorphisms of the signal transducer and activator of transcription 6 gene (STAT6) could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV).	peginterferon	299-312	signal transducer and activator of transcription 6	Homo sapiens	66-116
23651608-2	2013	This study aimed to evaluate whether genetic polymorphisms of the signal transducer and activator of transcription 6 gene (STAT6) could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV).	peginterferon	299-312	signal transducer and activator of transcription 6	Homo sapiens	123-128
23461440-1	2012	INTRODUCTION: The new protease inhibitors (PIs), telaprevir and boceprevir, with peginterferon and ribavirin, have increased the response rate in patients with genotype 1 chronic hepatitis C. Both are metabolized by CYP3A and they are CYP3A inhibitors.	peginterferon	81-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	216-221
23461440-1	2012	INTRODUCTION: The new protease inhibitors (PIs), telaprevir and boceprevir, with peginterferon and ribavirin, have increased the response rate in patients with genotype 1 chronic hepatitis C. Both are metabolized by CYP3A and they are CYP3A inhibitors.	peginterferon	81-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	235-240
21739446-1	2011	An association has been reported between genetic polymorphism near IL28B gene and the prevalence of mutation of hepatitis C virus (HCV) core region residue 70, both of which have been associated with a lack of virologic response to antiviral combination therapy with peginterferon (PEG-IFN) and ribavirin.	peginterferon	267-280	interferon lambda 3	Homo sapiens	67-72
32898985-0	2012	Erratum to: "Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin" [J Hepatol 2012;56:34-40].	peginterferon	128-141	interferon lambda 3	Homo sapiens	13-28
22612303-1	2012	BACKGROUND: Polymorphisms in the IL-28B region are a strong predictor of sustained virologic response (SVR) in individual studies of HCV genotype 1 patients receiving peginterferon (pegIFN) and ribavirin.	peginterferon	167-180	interferon lambda 3	Homo sapiens	33-39
21703176-0	2012	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.	peginterferon	115-128	interferon lambda 3	Homo sapiens	0-15
21063486-10	2010	CONCLUSION: CHC patients had a higher hs-CRP level than healthy controls which could be ameliorated after peginterferon/ribavirin combination therapy.	peginterferon	106-119	C-reactive protein	Homo sapiens	41-44
22174846-6	2011	It was also revealed that IL28B and STAT1-nuclear translocation in hepatocytes are independent predictors of response to treatment with peginterferon and ribavirin in chronic hepatitis C patients.	peginterferon	136-149	interferon lambda 3	Homo sapiens	26-31
22174846-6	2011	It was also revealed that IL28B and STAT1-nuclear translocation in hepatocytes are independent predictors of response to treatment with peginterferon and ribavirin in chronic hepatitis C patients.	peginterferon	136-149	signal transducer and activator of transcription 1	Homo sapiens	36-41
22003405-1	2011	BACKGROUND: Genetic studies have demonstrated a strong association between single nucleotide polymorphisms (SNPs) at IL28B and response to treatment with peginterferon (PEG) and ribavirin (RBV) in HCV monoinfected persons.	peginterferon	154-167	interferon lambda 3	Homo sapiens	117-122
17393513-6	2007	Peginterferon induces long-term remissions in disease in one-third of patients with typical hepatitis B e antigen (HBeAg) positive chronic hepatitis B, but a lesser proportion of those without HBeAg.	peginterferon	0-13	capsid protein;pre-capsid protein	Hepatitis B virus	92-113
17393513-6	2007	Peginterferon induces long-term remissions in disease in one-third of patients with typical hepatitis B e antigen (HBeAg) positive chronic hepatitis B, but a lesser proportion of those without HBeAg.	peginterferon	0-13	capsid protein;pre-capsid protein	Hepatitis B virus	115-120
17048997-13	2006	The treatment of insulin resistance by decreasing hyperinsulinemia could improve sustained response rates in patients with chronic hepatitis C treated with peginterferon plus ribavirin.	peginterferon	156-169	insulin	Homo sapiens	17-24
14987324-6	2004	CONCLUSIONS: Circulating and intrahepatic T-helper-1-associated chemokines are abnormally elevated in patients with chronic hepatitis C. Increased baseline serum interferon-gamma-inducible protein-10 levels in genotype 1-infected patients are associated with virological non-response to peginterferon plus ribavirin combination therapy.	peginterferon	287-300	C-X-C motif chemokine ligand 10	Homo sapiens	162-199